WEEKLY 008 · EDITION RECORD
Patient-specific cancer treatment, shared experimental foundations for cell AI, and ACE abundance and function. Three readings and an insight on the value of patient-specific data built on shared knowledge.
Commercialization
Delivering a different drug for each patient requires consistent quality and timing. Clinical results and the Tempus collaboration reveal what an individualized cancer-vaccine business needs.
R&D Allocation
Research institutions, government and companies are investing in experimental data for cell-response models. The test is whether those models can predict unmeasured conditions.
Frontier Science
ACE abundance was lower in early-stage psychosis, without a significant group difference in measured serum activity. Depression research provides context for separating abundance, catalytic activity and localization.
This issue’s insight: Shared knowledge and the data each patient still needs →
Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory.
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
Linked approval; uptake and payment open
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
Institutional report; independent verification open
The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs.
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons.
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts.
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
Mouse tasks with different actions and a shared reward delay showed shared cortical activity and task-dependent cerebellar separation that preserved temporal structure. A computational model combined faster learning with reduced interference.
European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression.
A common-condition study of 511 sequences from 29 organizations found different performance in improvement and ranking tasks. Cradle’s high-affinity candidate passed the aggregate threshold but retained concerns in individual developability assays.
Flexible electrodes tracked the same mouse neurons over months. Aligning activity across recording days improved decoding of temporal information in a repeated movie. The analysis also used responses from the new day.
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
Within 24 hours of immune stimulation in mice, developmental abnormalities were reported in roughly 30% of fetuses, limited to a subset of males. Affected fetuses also showed placental inflammatory changes, structural disruption and immune-cell and cytokine accumulation in amniotic fluid.
The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
The Virtual Biology Initiative expands joint experimental-data infrastructure. Separately, Arc’s 2026 challenge tests response prediction without providing perturbation outcomes in the target cells.
The study reports lower ACE protein abundance associated with early-stage psychosis and treatment resistance, but no significant group difference in enzyme activity per unit serum volume.
The archive stores complete article text, public evidence references, event dates, scheduled/observed distinctions, topic states and disclosed series. It contains no mailbox identifiers or private email bodies.
Editorial record window: 2026-10-24 — 2026-10-24 / Method: editorial-events-v1